Janine L.

Led cell-based and preclinical studies supporting the development of gene therapy approaches for the treatment of inherited CNS disorders.

• Probed the molecular mechanisms underlying autism through the development and characterization of novel mouse models of autism-associated genes, including Mecp2, Neurexin1 and Cdkl5 • Applied gene editing techniques to generate a mouse model with a targeted gene deletion. • Developed approaches coupled with next-generation sequencing/genomic studies to investigate the molecular function of MeCP2

• Elucidated how MeCP2 mutations drive Rett Syndrome pathology via mouse model studies, contributing to the discovery of novel therapeutic approaches • Generated gene-targeted and transgenic mice for functional and preclinical research • Designed and executed in vitro cell-based assays to complement in vivo studies • Recipient of a two-year Mentored Training Fellowship Award from the International Rett Syndrome Foundation ($100,000)

• Investigated the molecular function of GATA1 acetylation during erythroid development and identified the bromodomain protein BRD3 as a novel GATA1 interacting partner. • Recipient of an NIH Predoctoral Training Grant in Hemostasis and Thrombosis (2006-2011) • Recipient of an American Society of Hematology (ASH) Travel Award (2010)

• Implemented a comparative proteomic approach to elucidate the differences between the extracellular proteomes (secretomes) of three isogenic strains of B. anthracis • Utilized two-dimensional gel electrophoresis followed by computer-assisted gel image analysis and mass spectrometry to uncover several putative B. anthracis virulence factors